X4 Pharmaceuticals, Inc. (XFOR)
2.77
-0.13
(-4.48%)
USD |
NASDAQ |
Oct 06, 16:00
X4 Pharmaceuticals Enterprise Value : 134.91M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 134.91M |
| October 05, 2026 | 147.41M |
| October 02, 2026 | 140.68M |
| October 01, 2026 | 140.68M |
| September 30, 2026 | 147.41M |
| September 29, 2026 | 147.41M |
| September 28, 2026 | 158.46M |
| September 25, 2026 | 157.98M |
| September 24, 2026 | 157.02M |
| September 23, 2026 | 167.59M |
| September 22, 2026 | 198.35M |
| September 21, 2026 | 204.60M |
| September 18, 2026 | 212.77M |
| September 17, 2026 | 205.08M |
| September 16, 2026 | 206.04M |
| September 15, 2026 | 216.61M |
| September 14, 2026 | 216.61M |
| September 11, 2026 | 205.08M |
| September 10, 2026 | 195.47M |
| September 09, 2026 | 214.69M |
| September 08, 2026 | 205.56M |
| September 04, 2026 | 256.98M |
| September 03, 2026 | 256.98M |
| September 02, 2026 | 256.98M |
| September 01, 2026 | 259.86M |
| Date | Value |
|---|---|
| August 31, 2026 | 256.98M |
| August 28, 2026 | 256.98M |
| August 27, 2026 | 275.24M |
| August 26, 2026 | 269.47M |
| August 25, 2026 | 268.51M |
| August 24, 2026 | 257.94M |
| August 21, 2026 | 256.98M |
| August 20, 2026 | 256.02M |
| August 19, 2026 | 268.51M |
| August 18, 2026 | 273.32M |
| August 17, 2026 | 281.97M |
| August 14, 2026 | 274.28M |
| August 13, 2026 | 281.01M |
| August 12, 2026 | 281.01M |
| August 11, 2026 | 280.05M |
| August 10, 2026 | 277.16M |
| August 07, 2026 | 314.65M |
| August 06, 2026 | 269.47M |
| August 05, 2026 | 267.55M |
| August 04, 2026 | 281.01M |
| August 03, 2026 | 261.78M |
| July 31, 2026 | 251.21M |
| July 30, 2026 | 253.13M |
| July 29, 2026 | 253.13M |
| July 28, 2026 | 246.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics, Inc. | 2.086B |
| Arrowhead Pharmaceuticals, Inc. | 8.460B |
| Oncolytics Biotech, Inc. | 70.87M |
| Sangamo Therapeutics, Inc. | 49.74M |
| Anixa Biosciences, Inc. | 89.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.16M |
| Revenue (Quarterly) | 8.806M |
| Total Expenses (Quarterly) | 24.96M |
| EPS Diluted (Quarterly) | -0.1279 |
| Gross Profit Margin (Quarterly) | 81.24% |
| Profit Margin (Quarterly) | -183.5% |
| Earnings Yield | -43.09% |
| Normalized Earnings Yield | -42.81 |